ARTICLE | Finance
Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
July 28, 2014 7:00 AM UTC
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) gained $5.79 to $167.04 last week after EMA accepted and granted accelerated assessment to an MAA for asfotase alfa to treat hypophosphatasia (HPP). The company expects to complete a rolling BLA submission to FDA for the product this fall.
Alexion also reported 2Q14 earnings that beat the Street, including $512.5 million in 2Q14 sales for Soliris eculizumab (see "EPS Watch," page 20)...